Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-21-041602

Chief Executive Officer sold 30,000 shares at an average $126.43 ($3,792,804)

  • Chief Executive Officer acquired 30,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Kulkarni Samarth Chief Executive Officer 2021-06-15 Option exercise +30,000 $12.57 $377,100 217,719 D
Kulkarni Samarth Chief Executive Officer 2021-06-15 Sale −10,383 $125.39 $1,301,924 207,336 D
Kulkarni Samarth Chief Executive Officer 2021-06-15 Sale −16,129 $126.86 $2,046,125 191,207 D
Kulkarni Samarth Chief Executive Officer 2021-06-15 Sale −3,488 $127.51 $444,755 187,719 D
Derivatives
Kulkarni Samarth Chief Executive Officer 2021-06-15 Option exercise · Stock Option (Right to Buy) −30,000 63,333 D
Open-market sales · 30,000 sh · avg $126.43 · $3,792,804
Loading xslF345X03/doc4.xml…